Advanced Heart Failure Management. Dr Andrew Hannah Consultant Cardiologist Aberdeen Royal Infirmary

Similar documents
Heart failure: Local solutions for a growing problem

Heart Failure in 2012 with reference to NICE Guidance Dr Maurice Pye Consultant Cardiologist York District Hospital

Cardiology. Presented by: Dr Paul Bethell GP Lead for Planned Care

BSH Heart Failure Day for Revalidation and Training 2017

Inverclyde CHP Protected Learning Event- Heart Failure

A patient with decompensated HF

Atrial Fibrillation Cases. Dr Paul Broadhurst Consultant Cardiologist

8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)

Heart Failure. Jay Shavadia

Heart Failure A Disease for the Internist?

Heart Failure Clinician Guide JANUARY 2018

Heart Failure Clinician Guide JANUARY 2016

Heart Failure (HF) - Primary Care Flow Charts. Pre diagnosis Symptoms or signs suggestive of HF

Heart Failure (HF) - Primary Care Flow Charts. Symptoms or signs suggestive of HF. Pre diagnosis. Refer to the Heart Failure Clinic at VHK for

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

The NEW Heart Failure Guidelines

Theme - Women and Heart Failure

Heart Failure from a GP perspective

More acute cardiology

Congestive Heart Failure or Heart Failure

Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham

State-of-the-Art Management of Chronic Systolic Heart Failure

ICD deactivation Patient Journey

Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -

Antialdosterone treatment in heart failure

Beta-blockers in heart failure: evidence put into practice

ESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309

1000 Lives Key Components of Reliable, Evidence-Based Chronic Heart Failure Care how do we compare?

NHS GRAMPIAN MEDICAL TREATMENT GUIDELINES FOR CHRONIC HEART FAILURE (CHF) DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)

Heart Failure Dr Eric Klug Sunninghill, Sunward Park, CM Johannesburg Academic Hospital

LITERATURE REVIEW: HEART FAILURE. Chief Residents

Update on Palpitations and AF February 28 th 2018

Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF

The Failing Heart in Primary Care

Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update)

NT-proBNP: Evidence-based application in primary care

Faiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm

Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists

ARNI (Angiotensin Receptor blocker / Neprilysin Inhibitors [Sacubutril/Valsartan]) Heart Failure Medication Initiation and Titration

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Management of Heart Failure from diagnosis to the grave. Richard Lawrance Consultant Cardiologist - WMH

HEART FAILURE: PHARMACOTHERAPY UPDATE

Heart Failure. GP Update Refresher 18 th January 2018

was admitted to the Cardiology Service at the from Y /M /D to Y / M / D under the care of Dr..

Heart Failure Acute and Chronic

Cardiovascular Clinical Practice Guideline Pilot Implementation

Contemporary heart failure management. Dr Joris Mekel GP meeting 26 March 2015

Pharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014

Aldosterone Antagonism in Heart Failure: Now for all Patients?

Heart Failure 101 The Basic Principles of Diagnosis & Management

Heart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist

Diagnosis and management of chronic heart failure

HEART FAILURE. Study day November 2017 Sarah Briggs and Janet Laing

Charles Spencer MD, FRCP Consultant Cardiologist Mid Staffs NHSFT

ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR

Heart Failure in Women

Dobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure

ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure

Sliwa et al. JACC 2004;44:

IN-HF on line: patient settings (Enrollement period= )

Heart Failure. Dr. William Vosik. January, 2012

Heart Failure New Drugs- Updated Guidelines

Sandwell Community Heart Failure Team. Community Heart failure Specialist Nurses: Hilda O Keeffe- Henry and Jacqui Elson-Whittaker

Guideline-Directed Medical Therapy

All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014

HEART FAILURE SUMMARY. and is associated with significant morbidity and mortality. the cornerstone of heart failure treatment.

Epidemiology of Symptomatic Heart Failure in the U.S.

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides

Heart Failure Treatments

HEART FAILURE. Study day November 2018 Sarah Briggs

Coronary Heart Disease. Iqbal Malik

Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation

Combination of renin-angiotensinaldosterone. how to choose?

The Patient Journey through Heart Failure Primary Care Handout

Cardiac resynchronisation therapy (biventricular pacing) for the treatment of heart failure

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology

CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011

Checklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute

Relationship between cardiac dysfunction, HF and HF rendered asymptomatic

Evaluation of a diagnostic pathway in heart failure in primary care, using electrocardiography and brain natriuretic peptide guided echocardiography

Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study

Congestive Heart Failure 2015

Update on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy

Sara O. Weiss, MD Director, Heart Failure Services Virginia Mason Medical Center September 8, 2012

WHAT IS CONGESTIVE HEART FAILURE?

Therapeutic Targets and Interventions

Cardiac Resynchronization ICD Therapy: What is New?

ALLHAT. U.S. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute

HF and CRT: CRT-P versus CRT-D

Heart Failure with preserved ejection fraction (HFpEF)

Acute heart failure, beyond conventional treatment: persisting low output

DISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE

ICD Guidelines: who benefits from an ICD?

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:

New Strategies For Treating Patients With Chronic Heart Failure

Chronic. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Michael G. Shlipak, MD, MPH

National Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008

Transcription:

Advanced Heart Failure Management Dr Andrew Hannah Consultant Cardiologist Aberdeen Royal Infirmary

Grading of heart failure

Mr WY age 73 3/12 dyspnoea, fatigue and some ankle oedema PMH: hypertension 10 yrs, hyperchol, anterior MI 2006, PCI to LAD and occluded RCA 2006, severe LVSD last echo 2009 DH: aspirin, simva 40, ramipril 10mg, carvedilol 12.5mgbd, frusemide 80mg/day Ex smoker little alcohol OE: SR 90 BP 105/65 JVP raised, mild oedema, chest few creps, no murmurs Renal function normal, FBC normal CXR cardiomegaly,? Mild oedema What next?

Next steps Educate regarding fluid intake, weight monitoring Increase frusemide to 120mg/day Add spironolactone Watch U+Es: check 1 week, 4 weeks and 3 monthly Anything else? Refer cardiology

RALES: All-Cause Mortality NYHA III-IV Probability of survival 1.00 0.95 0.90 0.85 0.80 0.75 0.70 0.65 0.60 0.55 Placebo + ACE inhibitor + loop diuretic ± digitalis Risk reduction 30% 95% CI (18%-40%) p < 0.001 Aldosterone receptor antagonist + ACE inhibitor + loop diuretic ± digitalis 0.50 0.45 0 3 6 9 12 15 18 21 24 27 30 33 36 Months Pitt B et al, N Engl J Med 1999; 341: 709-717

Spironolactone or eplerenone Monitor U+Es carefully after introduction U+Es at 1 week, 2-4 weeks then 3 monthly (usually do not start if creat >170ish) K+ >5.5 but <6 reduce dose, if concomitant worsening renal function then stop. And start at lower dose once renal fx stabilised Beware inter-current illness: especially with renal impairment Advice patients who develop D+V or anorexia to stop spiro and seek medical/hfsn review

Why refer to cardiology? NYHA III with LBBB Suitable for CRT +/- ICD Even if less symptomatic consider ICD

Cardiac resynchronisation therapy (CRT) the theory In patients with CHF and LBBB not only is there poor LV contraction but dyssynchronous contraction Cardiac resynchronisation therapy can improve these factors and increase cardiac performance Biventricular pacing

CRT (cardiac resynchronisation therapy): Biventricular pacemaker

<>

Which patients should be considered for CRT? NYHA III-IV despite maximum (tolerated) medical therapy Evidence of conduction abnormalities (QRS >120ms:ideally LBBB) No major co-morbidity likely to be fatal in next 6-12 months or likely to be major contributor to poor QOL/SOB Age is not a contraindication

Issues regarding CRTs/ICDs CRT: 2+hours procedure, ICD 1hour Small risk of pneumothorax/tamponade Risk of infection, 1 in 40 cases failure to insert LV lead ICD: no driving for 1 month if primary prev, nil for 6months if scndry prev. Appropriate shock no driving 6months Inappropriate shocks no driving for up to 6months Box site pain sometimes, psychological problems

Mrs DP age 78 Increasing breathlessness 1 month, ankle odema to mid shin Known LVSD, hypertension, type II diabetes Carvedilol 6.25mgbd, ramipril 10mg, spiron 25mg, frus 80mg, aspirin, simvastatin Pulse 105, BP 110/60, jvp raised, peripheral odema, s1s2 no murmurs, dull bibasally but chest otherwise clear K+ 4.7, U12, cr 135, Hb 125 What next? ECG

ECG important in decompensated HF

What do you now want to achieve?...what dug changes? Warfarin and stop aspirin Increase frusemide Improve rate control how? But increasing carvedilol when pt in overt HF may be risky Add digoxin 125ug/day (perhaps give 250-500ug loading x2) Review in 1 week

1 week later VR 80, BP 110/65, odema better, feels less breathless What next? Increase carvedilol 12.5 bd Review 1 week

1 week later Feels better, no clinical HF U 12 cr 145 k 4.5 HR 62 What next? Stop digoxin and increase carv to 25mg bd

Patients (n) Mean Follow-up NYHA Class LVEF (%) Effects on all-cause mortality HF CIBIS 641 1.9yrs III-IV <40 All-cause mortality: 20% (p=0.22) CIBIS-II 2647 1.3yrs III-IV 35 All-cause mortality: 34% (p<0.0001) MERIT-HF 3991 1yr II IV 40 All-cause mortality: 34% (p=0.0062) US Carvedilol HF Study 1094 6.5mths II IV 35 All-cause mortality: 65% (p<0.001) COMET 3029 4.9yrs II-IV <35 All-cause mortality: 17%(p=0.0017) Post-MI HF CAPRICORN 1959 1.25yrs N/A <40 All-cause mortality: 23%(p=0.03)

ESC guidance 2010

Mr PD age 75 Recent admission with decompensated HF Severe LVSD, moderate functional MR, moderate pulmonary hypertension, moderate TR Narrow QRS, SR 90bpm K 5.0, u18, cr 205 Ramipril 2.5 bd, bumetanide 3mg bd, aspirin, simvastatin BP 92/65 JVP high, moderate peripheral odema, chest: small bibasal effusions but no crepitations Still NYHA III-IV

Reviewed by HFSN: yes What next? Add thiazide or increase loop diuretic BFZ useful if renal function reasonable Otherwise metolazone: 2.5mg every 2-3 days in primary care, U+Es 2x/week, watch K+, Na++ and renal function Not spironolactone: renal failure too poor

Must monitor closely: HFSN v helpful Slow improvement in odema nd dyspnoea over 2-3 weeks Hr 90, BP 95/60 U 24, cr 250, k 4.0 but stable Trace odema only Weight now static and 8kg less than pre-metolazone What next? Now try to commence carvediolol 3.125 bd Educate re side effects, daily weights, close monitoring, may need increased diuretics if starts to decompensate

Carvediolol in advanced CHF: COPERNICUS

Other drug options in advanced HF Digoxin in SR sometimes: perhaps can improve symptoms, rarely used now in UK Ivabradine: only if SR, HR >70 despite max tolerated dose of BB (decent option if cannot have BB at all eg significant asthma) ACEI/ARB intolerant due to renal failure: hydralazine and nitrate

Reducing re-admissions 30% re-admission rate for decompensated HF at 3 months HFSN review early post discharge GP review early post discharge Good patient education: self management, weights Optimise drug therapy Avoid stopping important drugs during decompensations esp betablockers Consider CRT devices in timely fashion

Which HF patients should be referred to cardiology? Probably the majority of patients with LVSD should have a cardiology evaluation at some point If diagnostic or aetiological doubt, particularly younger patients, as coronary angiography may be indicated Assessment for primary prevention ICD If angina present -? revascularisation Uncontrolled atrial fibrillation/flutter -? Tachycardia related cardiomyopathy If LBBB present: higher risk,? Suitable for CRT Syncope or presyncope:?vt,?needs ICD concerns over concomitant valvular dysfunction eg MR If difficulties establishing full medical therapy Difficulties controlling symptoms